130 – Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase
Background Twice-yearly subcutaneous lenacapavir (LEN) is a HIV-1 capsid (CA) inhibitor approved for HIV pre-exposure prophylaxis (PrEP) based on efficacy and safety from the PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) Phase 3 studies. The primary analyses demonstrated that acquisition of HIV while receiving LEN and emergent resistance during the studies were rare. Here, we…